OPKO Health (NASDAQ:OPK) Sees Strong Trading Volume - Time to Buy?

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) saw unusually-high trading volume on Monday . Approximately 7,412,277 shares were traded during mid-day trading, an increase of 179% from the previous session's volume of 2,659,488 shares.The stock last traded at $1.52 and had previously closed at $1.52.

Wall Street Analyst Weigh In

OPK has been the subject of several recent analyst reports. Barrington Research restated an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a research note on Friday, November 8th. HC Wainwright restated a "buy" rating and issued a $3.00 price target on shares of OPKO Health in a research note on Wednesday, January 8th. Finally, StockNews.com lowered OPKO Health from a "hold" rating to a "sell" rating in a research note on Wednesday, January 15th.

OPKO Health Trading Down 0.6 %

The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -8.47 and a beta of 1.63. The company has a fifty day moving average of $1.52 and a 200-day moving average of $1.52.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.13. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The company had revenue of $173.60 million for the quarter, compared to analysts' expectations of $181.32 million. During the same period in the previous year, the firm posted ($0.11) EPS. As a group, equities research analysts anticipate that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Phillip Md Et Al Frost bought 500,000 shares of the stock in a transaction dated Wednesday, December 11th. The shares were acquired at an average cost of $1.56 per share, for a total transaction of $780,000.00. Following the acquisition, the chief executive officer now directly owns 212,411,477 shares in the company, valued at approximately $331,361,904.12. This trade represents a 0.24 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders have bought 1,721,609 shares of company stock worth $2,634,710. Insiders own 47.26% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC boosted its holdings in shares of OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 11,089 shares during the last quarter. Algert Global LLC acquired a new position in OPKO Health in the second quarter valued at approximately $44,000. Orion Portfolio Solutions LLC acquired a new position in OPKO Health in the third quarter valued at approximately $45,000. Ieq Capital LLC acquired a new position in OPKO Health in the fourth quarter valued at approximately $52,000. Finally, Private Advisor Group LLC lifted its holdings in OPKO Health by 242.7% in the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company's stock valued at $53,000 after acquiring an additional 25,000 shares during the last quarter. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.